Economic Evaluation of a Pharmacogenetic Dosing Algorithm for Coumarin Anticoagulants in the Netherlands

Pharmacogenomics - United Kingdom
doi 10.2217/pgs.14.149
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Future Medicine Ltd

Related search

Drug Interactions With Coumarin Derivative Anticoagulants.

BMJ
1982English

A Cost Utility Analysis of CYP2D6 Pharmacogenetic Guided Dosing Versus Standard Dosing of Risperidone for Treatment of Schizophrenia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Applications of Pharmacogenetic Testing for Personalization of Therapy With Oral Anticoagulants in Russia

Rational Pharmacotherapy in Cardiology
Cardiovascular MedicinePharmacologyCardiology
2013English

Pmh39 - Health-Economic Evaluation of Pharmacogenetic Tests in Psychiatric In-Patient Care

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

CYP2C9*8is Prevalent Among African–Americans: Implications for Pharmacogenetic Dosing

Pharmacogenomics
Molecular MedicineGeneticsPharmacology
2009English

The Risk of Overanticoagulation in Patients With Heart Failure on Coumarin Anticoagulants

British Journal of Haematology
Hematology
2004English

Evaluation of a Pharmacogenetic Educational Toolkit for Community Pharmacists

Pharmacogenomics
Molecular MedicineGeneticsPharmacology
2016English

Coumarin Anticoagulants and Co-Trimoxazole: Avoid the Combination Rather Than Manage the Interaction

European Journal of Clinical Pharmacology
MedicinePharmacology
2007English

A CYP3A4 Phenotype-Based Dosing Algorithm for Individualized Treatment of Irinotecan

Clinical Cancer Research
Cancer ResearchOncology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy